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Abstract
Shortly after the discovery of human herpesvirus 6 (HHV-6), two distinct variants, HHV-6A and 
HHV-6B, were identified. In 2012, the International Committee on Taxonomy of Viruses (ICTV) 
classified HHV-6A and HHV-6B as separate viruses. This review outlines several of the 
documented epidemiological, biological, and immunological distinctions between HHV-6A and 
HHV-6B, which support the ICTV classification. The utilization of virus-specific clinical and 
laboratory assays for distinguishing HHV-6A and HHV-6B is now required for further 
classification. For clarity in biological and clinical distinctions between HHV-6A and HHV-6B, 
scientists and physicians are herein urged, where possible, to differentiate carefully between 
HHV-6A and HHV-6B in all future publications.
Introduction and classification history
In 1986, a new virus was isolated in the USA from patients with AIDS as well as 
lymphoproliferative disorders [111]. Initially designated “human B-lymphotropic virus 
(HBLV)”, the virus was renamed human herpesvirus 6 (HHV-6) (GS strain), following 
herpesvirus nomenclature guidelines, soon thereafter [2]. In 1987 and 1988, independent 
isolates were obtained from AIDS patients in Africa, designated U1102 (from Uganda) [50] 
and Z29 (from Zaire) [80, 124]. As other strains were isolated from various geographic 
regions and clinical settings, it became gradually apparent that all HHV-6 isolates could be 
included in one of two well-defined groups, differing in their molecular, epidemiological 
and biological properties [4, 16, 71, 113, 129]. The two groups showed different in vitro 
tropism for selected T cell lines, specific immunological reactivity with monoclonal 
antibodies, distinct patterns of restriction endonuclease sites, and specific and conserved 
interstrain variations in their DNA sequences [68, 69, 71].
In the early 1990s, the scientific community debated whether the two groups simply 
reflected a normal population heterogeneity within a single virus species [113], and in 1992 
a first consensus was reached to designate such groups as two variants of the same species: 
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HHV-6A and HHV-6B [1]. This decision was based on two main factors: (i) the interspecies 
divergence of nucleic acids was remarkably low and (ii) there was limited knowledge of 
differential epidemiology and pathogenic potential [1]. However, as new evidence continued 
to accrue, several authors began to suggest that the two variants be recognized as distinct 
viruses [22, 24, 32, 45].
Genomic sequencing has now confirmed distinctions between HHV-6A and HHV-6B and 
relationships to the herpesvirus family overall. The genomes of the these two viruses are co-
linear and share an overall identity of 90 %, but divergence of specific sequences [e.g., the 
immediate-early (IE) region] is higher than 30 %, some from splicing differences [47, 58, 
67], and there are clear functional differences in the IE1 gene of HHV-6A and HHV-6B [59, 
70]. Remarkably, even though the IE1 gene differs substantially between HHV-6A and 
HHV-6B, this region is highly conserved (>95 %) within clinical and laboratory isolates of 
each virus [116]. Analysis of different viral strains shows that even highly conserved 
sequences with homology higher than 95 %, such as gH, gB and U94, as well as divergent 
genes such as gN, gO, and U83 chemokine, are characterized by specific amino acid 
signatures, which permit distinctions between the two viruses [5, 56, 107]. Furthermore, 
several reports have shown that the splicing pattern and temporal regulation of transcription 
of selected genes are different [47, 67, 92, 102, 103]. So far, these distinctions and the 
absence of evidence of intervariant recombination in common circulating viruses suggest 
that the two groups do occupy different ecological niches in vivo [24].
An Ad Hoc Committee on HHV-6A & HHV-6B Genomic Divergence was formed in 2009 to 
generate an official proposal to recognize HHV-6A and HHV-6B as distinct viruses, which 
was submitted to the ICTV in 2010. In 2012, the ICTV officially ratified the classification of 
HHV-6A and HHV-6B as distinct viruses, replacing species Human herpesvirus 6 with 
Human herpesvirus 6A and Human herpesvirus 6B in the genus Roseolovirus, subfamily 
Betaherpesvirinae, family Herpesviridae, order Herpesvirales. Human herpesvirus 6A has 
been designated as the type species in this genus [6].
The following is a detailed summary of several known distinctions between HHV-6A and 
HHV-6B, which ultimately led or added support to the classification of these agents as 
separate and distinct viruses.
Distinct epidemiology and disease associations
1. In the USA, UK and Japan, 97–100 % of primary infections by these two viruses 
are caused by HHV-6B and occur between the ages of 6 and 12 months [43, 51, 
125, 130, 134]. Less is known about the epidemiology of HHV-6A infection. One 
report has indicated that HHV-6A infection is acquired later in life and that primary 
infection is typically without clinical symptoms [40]. However, several groups 
have now documented symptomatic HHV-6A primary infections amongst children 
from both the USA and Africa [18, 63]. In addition, HHV-6A was found to be the 
predominant virus associated with viremic infection in a pediatric population of 
Sub-Saharan Africa [18] and has also been shown to cause roseola and febrile 
disease in this population. In two separate studies, HHV-6A was detected in blood 
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DNA from hospitalized febrile HIV+ children from this geographic population [18, 
72]. Although this specific correlation awaits further confirmation from other tissue 
sites and from populations in other regions of Africa, this finding is potentially 
significant because HHV-6A has been proposed as a potential accelerating factor in 
HIV infection, as corroborated by the results of in vivo studies in macaques [19, 
87].
2. HHV-6A and HHV-6B have differential distributions in human tissues. HHV-6B is 
the dominant virus present in the peripheral blood mononuclear cells (PBMCs) of 
healthy adults, at least in industrialized countries, and is also the virus that 
reactivates in a significant majority of both solid organ and stem cell transplant 
cases in these countries [21, 28, 45, 53, 57, 65, 74, 100, 108, 128], while both 
HHV-6A and HHV-6B are detected with similar frequency in the plasma of bone 
marrow transplant patients [97, 114]. HHV-6B is also frequently detected in the GI 
tract of solid organ transplant patients [76], has been identified in endodontic 
abscesses [54], and is the virus found in adenoids and tonsils, particularly in 
children affected by upper airway infections [35]. HHV-6A has been found in 54 % 
of the lungs of healthy adults [36], although this requires confirmation in other 
studies and/or regions. Both HHV-6A and HHV-6B have been identified in 
vitreous fluid samples and implicated in ocular inflammatory diseases [34, 117]. 
However, it must be noted that these observed differential distribution patterns in 
human tissues may reflect, at least in part, the differing prevalence of the two 
viruses in separate geographic regions.
3. While HHV-6A and HHV-6B are both neurotropic, there is evidence suggesting an 
increased severity of HHV-6A over HHV-6B in cases of clinical neurological 
disease [21, 37, 40, 62]. In addition, although an overwhelming majority of post-
transplant reactivation occurs with HHV-6B [28, 29, 53], HHV-6A DNA and 
mRNA are found more frequently than HHV-6B in patients with 
neuroinflammatory diseases such as multiple sclerosis (MS) [9, 14, 48, 115] and 
rhomboencephalitis [37]. HHV-6A has been found predominantly in the CNS of a 
subset of patients with MS, and active HHV-6A infection has been detected in 
blood [8, 9, 11] and in CSF [110] of patients with relapsing/remitting MS [8–10, 
14, 20, 110, 115, 131]. Marmosets inoculated with HHV-6A intravenously 
exhibited neurological symptoms, whereas those inoculated with HHV-6B were 
asymptomatic [75]. A strain of HHV-6A has also recently been isolated from the 
fluid specimens from a glioma cyst [30]. Moreover, HHV-6A was identified in 72 
% of pediatric glial tumors [38].
4. HHV-6B, but not HHV-6A, has been associated with mesial temporal lobe epilepsy 
and status epilepticus [52, 77, 126].
5. HHV-6A, but not HHV-6B, has been associated with Hashimoto’s thyroiditis [25] 
as well as syncytial-giant cell hepatitis in liver transplant patients [9, 12, 13, 62, 82, 
91, 104–106].
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Distinct biological and immunological properties
1. Although both HHV-6A and HHV-6B have been reported to have a strong CD4+T-
lymphocyte tropism both in vitro and in vivo [31, 83, 96, 118], there are some 
important differences in their ability to infect cytotoxic effector cells [39]. While 
HHV-6A has been shown to productively infect CD8+ T cells, natural killer (NK) 
cells and gamma/delta T cells, inducing de novo expression of CD4 messenger 
RNA and protein that is otherwise not expressed in these cell subsets [84–86], 
HHV-6B can infect these cells very inefficiently, if at all [60, 90].
2. HHV-6B, but not HHV-6A, infects and induces CPE in Molt-3 cells, and HHV-6A, 
but not HHV-6B, infects and induces CPE in HSB-2 cells [1, 3, 4, 7, 78]. HHV-6A, 
but not HHV-6B, successfully replicates in human neural stem cells [41] and in 
human progenitor-derived astrocytes [49, 61]. Although only supporting low levels 
of infection, human fibroblast cell lines appear more permissive to HHV-6A than 
HHV-6B in vitro but still require copropagation with PBMCs [109]. HHV-6B 
infection in the astrocytic cell line U251 leads to abortive infection, whereas with 
HHV-6A, it leads to replication [49, 133]. HHV-6A, but not HHV-6B, can replicate 
in oligodendrocyte progenitor cells [7, 46, 49].
3. Variation in cellular tropism may be related to the use of alternative cellular 
receptors by the two viruses. Although both HHV-6A and HHV-6B have been 
shown to utilize CD46 as a cellular receptor [112, 121], the modality and/or affinity 
of receptor interaction seem to differ between the two viruses. It has been 
suggested that HHV-6A (U1102 or GS), but not HHV-6B, can induce CD46-
mediated cell-cell fusion without viral replication [93] through a tetrameric 
complex composed of glycoproteins gH, gL, and gQ1, and gQ2 [94, 122]. 
However, some groups have reported that HHV-6B is also able to induce cell-cell 
fusion without viral replication [99].
4. CD134, a member of the TNF receptor superfamily present on activated T 
lymphocytes, has recently been identified as a receptor molecule for HHV-6B, 
selectively interacting with the gH/gL/gQ1/gQ2 complex of HHV-6B [123].
5. The HHV-6A and HHV-6B gO gene products have 76.8% amino acid sequence 
identity, which is much lower than the identity between other glycoproteins. The 
lower identity suggests that the gH–gL–gO complex may confer at least some of 
the different biological properties on HHV-6A and HHV-6B that cause them to 
target different cells [18, 95, 122].
6. Variations in cellular tropism may also be related to the ability to chemoattract 
distinct cellular populations via specific virus chemokines. Chemokine U83B from 
HHV-6B is specific for CCR2 and can chemoattract cells for latent or lytic 
infection that bear this receptor, such as monocytic cells and some T cell 
subpopulations. In contrast, chemokine U83A from HHV-6A has broader 
specificity for CCR1, CCR4, CCR5, CCR6 and CCR8, which are present on 
monocytic/macrophage, dendritic, NK, plus activated and skin-homing T cells [27, 
33, 44, 88]. Of note, U83 is also one of the few hypervariable genes that is specific 
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for HHV-6A and HHV-6B but not shared with the related HHV-7 and therefore 
encodes key distinctions for these viruses [33, 56].
7. The glycoprotein-encoding genes that encode gQ (U97, 98, 99 and 100) of 
HHV-6A and HHV-6B share only 72.1% sequence identity [67]. This glycoprotein 
may therefore have a role in the differential effects of HHV-6A and HHV-6B 
infections. gQ1, along with gB and gH, contains epitopes recognized by 
neutralizing antibodies and represents a target for virus-specific neutralizing 
antibodies [73, 89, 98, 102, 103, 120]. The gH/gL/gQ1/gQ2 complex is an 
important target for virusneutralizing antibodies [89, 95].
8. HHV-6B, but not HHV-6A, was shown to be resistant to the antiviral effects of 
interferon-α and –β due to silencing of interferon-stimulated genes [70].
9. Although HHV-6A and HHV-6B stimulate crossreactive T-cell responses because 
they share more than 88 % sequence homology, it has been reported that at least 7 
%of the T-cell clones that are reactive to HHV-6 demonstrate a specific and distinct 
pattern of proliferation either to HHV-6A or HHV-6B in vitro [132].
10. Several monoclonal antibodies are virus-specific. For example, 2E2 (reacting with 
gp110), 2-D6 (reacting with gp82/105), 13-D6 (reacting with gp82/105) [17], C-5 
(reacting with p38/41) [68], p6H8 (reacting with IE-2) [15, 127], and gp110 
(reacting with 2E2) [68] are specific for HHV-6A, while OHV-3 (reacting with 
p98) [17, 79, 119] and C3108-103 (reacting with 101K/U11) [101] are specific for 
HHV-6B.
11. There are functional differences between cells infected with HHV-6A vs. HHV-6B 
affecting inflammation [33].
Distinction of HHV-6A vs. HHV-6B in publications
The lack of clear distinction between HHV-6A and HHV-6B in the literature makes it 
difficult to properly assess epidemiological differences and etiologic associations. In light of 
the ICTV’s official reclassification, the utilization of virus-specific clinical and laboratory 
assays for HHV-6A and HHV-6B is especially crucial [23, 26, 64, 66]. However, because 
HHV-6A can be present at lower copy numbers than HHV-6B, assays that rely strictly on 
melting point analysis for differentiation may be biased toward the detection of HHV-6B, 
resulting in further confusion [81]. Moreover, reliance on single SNPs, for example in 
restriction enzyme assays or using ‘specific’ primers or probes in real-time PCR assays, can 
be misinterpreted due to strain variation unless an extensive characterization of laboratory-
adapted and clinical strains has been performed [26]. Furthermore, serology currently cannot 
differentiate between HHV-6A and HHV-6B. To avoid this complication, the use of 
comprehensive virus-specific assays is preferred, combined with confirmation using 
nucleotide sequencing [18, 26, 42, 55, 57]. In an effort to bring additional clarity to the 
important biological and clinical distinctions between HHV-6A and HHV-6B, we herein 
urge scientists and physicians to carefully differentiate, whenever possible, between 
HHV-6A and HHV-6B in all future publications.
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